New perspectives on targeted therapy in ovarian cancer

Jermaine IG Coward1,3
Kathryn Middleton1
Felicity Murphy1

1Mater Health Services, Raymond Terrace, South Brisbane, QLD, Australia; 2Inflammation and Cancer Therapeutics Group, Mater Research, University of Queensland, Translational Research Institute, Woolloongabba, Brisbane, QLD, Australia; 3School of Medicine, University of Queensland, Brisbane, QLD, Australia

Correspondence: JIG Coward
Inflammation & Cancer Therapeutics Group, Mater Research, University of Queensland, Level 4, Translational Research Institute, 37 Kent Street, Woolloongabba, Brisbane, QLD 4102, Australia
Email jim.coward@mater.uq.edu.au

Abstract: Epithelial ovarian cancer remains the most lethal gynecologic malignancy. During the last 15 years, there has been only marginal improvement in 5 year overall survival. These daunting statistics are compounded by the fact that despite all subtypes exhibiting striking heterogeneity, their systemic management remains identical. Although changes to the scheduling and administration of chemotherapy have improved outcomes to a degree, a therapeutic ceiling is being reached with this approach, resulting in a number of trials investigating the efficacy of targeted therapies alongside standard treatment algorithms. Furthermore, there is an urge to develop subtype-specific studies in an attempt to improve outcomes, which currently remain poor. This review summarizes the key studies with antiangiogenic agents, poly(adenosine diphosphate [ADP]-ribose) inhibitors, and epidermal growth factor receptor/human epidermal growth factor receptor family targeting, in addition to folate receptor antagonists and insulin growth factor receptor inhibitors. The efficacy of treatment paradigms used in non-ovarian malignancies for type I tumors is also highlighted, in addition to recent advances in appropriate patient stratification for targeted therapies in epithelial ovarian cancer.

Keywords: antiangiogenic therapy, high-grade serous, low grade ovarian cancer, PARP inhibition, cancer-related inflammation

Introduction

Epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy and the fifth most common cause of cancer-related death in women. The estimated annual incidence of this disease worldwide is just over 200,000 individuals, with approximately 125,000 deaths.1 Significant advances in the understanding of the natural history of the disease and thorough initial staging, along with surgical and chemotherapeutic management, have improved the short-term course of ovarian carcinoma. However, despite such improvements, most patients relapse after primary treatment and succumb to disease progression. The risk for ovarian cancer increases with age. The majority of patients are postmenopausal, with 80% of cases diagnosed being older than 50 years, and a peak incidence of 61.8 per 100,000 women is observed in the 60–64 year old age group (Cancer Research UK data). Racial and geographical variations are also evident for this disease. For example, lower incidences are seen in African-American and Afro-Caribbean women compared with their Caucasian counterparts.2,3 In addition, the rate of EOC is significantly higher in Europe and the United States compared with in Sub-Saharan Africa and Japan, respectively.4,5

Surgical management (consisting of total abdominal hysterectomy and bilateral salpingo-oophorectomy, together with omentectomy, peritoneal washings, and pelvic lymph node sampling) is essential to EOC diagnosis, staging, and treatment. The ultimate aim is to resect all macroscopic tumor (ie, optimal debulking) within the pelvis and to perform careful surveillance of the abdomen to detect any subtle sites of metastatic disease. The extent of debulking profoundly influences prognosis in EOC. With respect to optimally
debulled (<1 cm residual disease) and suboptimally debulled (>1 cm residual disease) patients, Chi et al reported significant differences in both 5 year progression-free survival (PFS) rates (31% versus 14%, respectively [hazard ratio (HR), 0.757; 95% confidence interval (CI), 0.601–0.953; \( P=0.01 \)]) and 5 year overall survival (OS) rates (47% versus 35%, respectively [HR, 0.764; 95% CI, 0.592–0.987; \( P=0.03 \)]).\(^8\)

With the exception of good-prognosis early-stage disease (ie, stage Ia and Ib, grade 1), in which standard care involves cytoreductive surgery followed by observation,\(^2\) chemotherapy remains the principal form of adjuvant and neoadjuvant treatment for EOC. During the last 40 years, a myriad trials have been conducted to establish a “gold standard” of therapy and to validate the optimal timing and mode of cytotoxic delivery. Arguably, the most significant initial advance in chemotherapeutic management was the introduction of paclitaxel to the treatment armamentarium. This was reported in the pivotal Gynecologic Oncology Group (GOG)-111 study in 1996 (\( n=386 \)), in which the combination of cisplatin and paclitaxel conferred a substantial survival advantage over cisplatin and cyclophosphamide (PFS, 18 versus 13 months \( P<0.001 \)); OS, 38 versus 24 months \( P<0.001 \)).\(^9\) After this, the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) study in 2000 (\( n=208 \)) established equivalent PFS (16 months) and OS (31 months) for cisplatin/paclitaxel and carboplatin/paclitaxel doublets.\(^10\) The toxicity profile favoring the carboplatin/paclitaxel regimen has now established this as standard of care in the first-line setting. Although numerous single agents (eg, gemcitabine, doxorubicin, topotecan) have known activity in recurrent disease, their addition to standard primary treatment failed to prolong survival.\(^11\) Only relatively recently has OS improved as a consequence of chemotherapy, with the Japanese Gynecologic Oncology Group (JGOG) 3016 (\( n=637 \)) study confirming superior efficacy by altering treatment schedules.\(^12\) This trial evaluated dose-dense treatment with weekly paclitaxel alongside carboplatin three times weekly against traditional administration three times weekly for both drugs. Median PFS was significantly extended in the dose-dense treatment group compared with in the conventional treatment group (28.2 months [95% CI, 22.3–33.8 months] versus 17.5 months [95% CI, 15.7–21.7 months]; HR, 0.76; 95% CI, 0.62–0.91; \( P=0.0037 \)). Importantly, median OS was 100.5 months (95% CI, 65.2–\( \infty \) months) in the dose-dense treatment group and 62.2 months (95% CI, 52.1–82.6 months) in the conventional treatment group (HR, 0.79; 95% CI, 0.63–0.99; \( P=0.039 \)).\(^12\)

As EOC has a predilection for peritoneal dissemination, there has been increasing interest in the role of intraperitoneal (ip) chemotherapy. One of the advantages of this approach relates to the higher concentrations of cisplatin and paclitaxel that can be achieved in the peritoneal cavity compared with plasma.\(^13\)\(^,\)\(^14\) One of the largest definitive studies testing this hypothesis in the first-line setting was the GOG 172 study.\(^15\) This study evaluated 417 patients with optimally debulled (<1 cm) stage III disease who were randomized to receive six courses every 3 weeks of either standard intravenous (iv) cisplatin/paclitaxel or iv paclitaxel (day 1) with ip cisplatin (day 2), followed by ip paclitaxel (day 8). Despite only 42% of the ip group completing all six cycles, this cohort had superior median PFS (23.8 versus 18.3 months; \( P=0.05 \)) and OS (65.6 versus 49.7 months; \( P=0.03 \)).\(^15\) However, ip therapy had a less favorable toxicity profile, with significant myelosuppression, neuropathy, and abdominal pain and poor quality of life and catheter complications.\(^15\) A recent update of this study at the 2013 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer confirmed that the 5 year OS rate among patients treated with ip therapy increased from 18% with the completion of one or two cycles to 33% with three or four cycles, to 59% for patients who completed five or six cycles of treatment.\(^16\)

These results are further substantiated by a subsequent systematic Cochrane review of nine randomized studies (\( n=2,119 \)), which confirms that in comparison with iv chemotherapy, ip administration confers a definite PFS advantage (five studies, 1,311 women; HR, 0.78; 95% CI, 0.70–0.86) and OS benefit (eight studies, 2,026 women; HR, 0.81; 95% CI, 0.72–0.90).\(^17\) Despite this, ip administration has yet to become an international standard of care and currently is usually reserved for patients who have optimally debulked or minimal residual disease. Furthermore, skepticism still exists about this approach in view of the significant toxicity and the possibility that any OS advantage may be a result of the weekly administration of paclitaxel as opposed to the ip delivery.

Although changes to both chemotherapy schedules and routes of administration are associated with improved survival, it appears that a therapeutic ceiling with these drugs has been reached. EOC still lags behind a number of common solid malignancies in terms of the sluggish incremental extension in OS during the last 20 years.\(^18\) Within this time, the advent of targeted therapy has undoubtedly revolutionized the therapeutic landscape in oncology. This review synthesizes the key studies using novel therapies either as single agents or alongside standard chemotherapy to improve the current dismal statistics for EOC.

**Antiangiogenic therapy**

**Bevacizumab**

EOC is unique among solid organ malignancies in its natural history, partly because of its pattern of spread within the...
peritoneum. Angiogenesis is thought to be particularly crucial in the persistence of EOC and so has been a key target in clinical research. Antiangiogenic agents have been evaluated extensively in the treatment of EOC and found to have some clinical efficacy, both as single agents as well as in combination with chemotherapy (Table 1). Bevacizumab, a monoclonal antibody that binds to the vascular endothelial growth factor (VEGF)-receptor ligand VEGF-A, has been most extensively investigated in clinical research. Phase II trials of bevacizumab alone in heavily pretreated patients demonstrated mixed results. In a Phase II trial of 62 patients, 13 patients (21.0%) experienced clinical responses (two complete responses [CR] and eleven partial responses [PR]; median duration, 10 months), and 25 patients (40.3%) survived progression-free for at least 6 months, with no gastrointestinal (GI) perforations.19 Another Phase II trial, which demonstrated a 15.9% PR rate, also found an 11% risk for GI perforation and was stopped early because of safety concerns. In this trial, the risk for GI perforation was highest in patients who had received three prior lines of treatment.20 This is the only trial to report such a higher rate of GI perforation with the use of bevacizumab.

The landmark GOG-218 and International Collaborative Ovarian Neoplasm group (ICON) 7 trials evaluated the addition of bevacizumab to carboplatin/paclitaxel in first-line therapy.21,22 ICON7 found that the greatest benefit of adding bevacizumab was seen in a higher-risk population with stage III–IV disease and residual disease greater than 1 cm. In this population, PFS at 42 months was 14.5 months with standard therapy alone and 18.1 months with bevacizumab added, with respective median OS of 28.8 and 36.6 months.22 On the basis of these trials, the European Society for Medical Oncology clinical practice guidelines suggest bevacizumab in addition to chemotherapy in patients with poor prognostic features, such as stage IV or suboptimally debulked disease.23

Interestingly, it appears that predictive biomarkers for this treatment are on the horizon. At the American Society of Clinical Oncology (ASCO) 2014 annual meeting, Gourley et al presented data that highlighted differential responses between patients in the ICON7 study exhibiting particular genomic signatures.24 Using unsupervised hierarchical clustering, Gourley et al identified three subgroups: one with angiogenic repression/immune gene upregulation (immune molecular subgroup) and two with angiogenic gene upregulation (proangiogenic subgroup). Using a 63-gene signature to separate these subgroups, in the chemotherapy control group, the immunogenic subgroup had a significantly superior PFS (HR, 0.47; 95% CI, 0.32–0.71; P<0.001) and OS (HR, 0.45; 95% CI, 0.26–0.79; P=0.005) compared with the proangiogenic groups.24 The authors hypothesized this

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Key bevacizumab studies in epithelial ovarian cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trial or author</td>
<td>Setting</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>-------------------------------------------------</td>
</tr>
<tr>
<td>GOG19</td>
<td>Recurrent disease</td>
</tr>
<tr>
<td>Cannistra et al20</td>
<td>Recurrent disease</td>
</tr>
<tr>
<td>GOG 21821</td>
<td>First line</td>
</tr>
<tr>
<td>ICON722</td>
<td>First line</td>
</tr>
<tr>
<td>OCEANS23</td>
<td>Recurrent disease</td>
</tr>
<tr>
<td>AURELIA24</td>
<td>Recurrent disease</td>
</tr>
</tbody>
</table>

Abbreviations: GOG, Gynecologic Oncology Group; PFS, progression-free survival; OS, overall survival; q 3/52, every 3 weeks.
could be a result of either improved antitumor immunity or less-developed tumor vascularity in the immunogenic group. However, patients with the proangiogenic gene signature had significantly improved PFS when treated with carboplatin/paclitaxel and bevacizumab (17.4 months) compared with chemotherapy alone (12.3 months). This contrasted with patients harboring an immunogenic/angiogenic repression gene signature where PFS was significantly impeded by the addition of bevacizumab ($P=0.015$), with a median PFS of 18.5 months when treated with bevacizumab compared with 35.8 months when receiving carboplatin/paclitaxel alone.24

In relapsed disease, both the OCEANS (Ovarian Cancer Study Comparing Efficacy and Safety of Chemotherapy and Anti-Angiogenic Therapy in Platinum-Sensitive Recurrent Disease) and AURELIA (Avastin Use in Platinum-Resistant Epithelial Ovarian Cancer) trials have evaluated the addition of bevacizumab to chemotherapy and demonstrated an improvement in PFS.25,26 In AURELIA, in patients with relapsed platinum-resistant ovarian cancer, median PFS was 3.4 months with chemotherapy alone versus 6.7 months with the addition of bevacizumab. Median OS was 13.3 months (95% CI, 11.9–16.4 months) with chemotherapy alone versus 16.6 months (95% CI, 13.7–19.0 months) with bevacizumab plus chemotherapy, which did not reach statistical significance, but 40% of patients receiving chemotherapy crossed over to single-agent bevacizumab on progression, compromising the OS data.26

In the OCEANS trial, the addition of bevacizumab to carboplatin/gemcitabine in patients with relapsed platinum-sensitive ovarian cancer also improved PFS, with PFS of 12.4 months in the chemotherapy plus bevacizumab group versus 8.4 months in the chemotherapy plus placebo group.25 OS data were not mature when this study was published, but the preliminary analysis did not demonstrate an OS difference, at 33.3 and 35.2 months for the bevacizumab and placebo groups, respectively.25 The large crossover in these trials also significantly affected the interpretation of OS data.

The benefit of the antiangiogenic agents does come at the cost of additional toxicity. In ICON7, the risks included increased risk from perforation, in addition to well-recognized toxicities including bleeding, thromboembolic events, and hypertension.27 The AURELIA study revealed a 2.2% risk for perforation with the addition of bevacizumab;26 however, the risk for perforation was lower than might have been expected, given that patients with ovarian cancer are at a higher risk for perforation than patients with other solid organ malignancies. In general, in these trials, it seems the increased risk for perforation with the addition of bevacizumab is small and does not outweigh its possible clinical benefit. Antiangiogenics are also being trialed in combination with agents other than cytotoxic chemotherapy. Both bevacizumab and cediranib (a VEGF2 inhibitor) have been combined with mammalian target of rapamycin (mTOR) inhibitors in clinical trials that are underway.28 Undeniably, the success witnessed with bevacizumab in various settings for EOC has provided a useful platform for the introduction of other antiangiogenic agents.

Aflibercept (VEGF trap)

Aflibercept is a heterodimeric molecule consisting of domains of vascular endothelial growth factor 1 (VEGFR1) and VEGFR2 with immunoglobulin G Fc. Although it has a lower molecular weight than bevacizumab, it possesses a higher affinity for VEGF isoforms including VEGF-A, VEGF-B, and placental growth factor.29 Inevitably, this broader spectrum of antiangiogenic activity led to a number of Phase II studies in recurrent EOC. Coleman et al treated 46 patients in this setting with a combination of aflibercept (6 mg/kg iv) and docetaxel (75 mg/m2 iv) every 3 weeks until evidence of progressive disease.30 They reported an impressive 54% objective response rate (ORR), which included ten patients with CR and a median PFS and OS of 6.2 months and 24.3 months, respectively.30 In view of the intricate links between VEGF signaling and development of ascites, subsequent studies with aflibercept have focused on its potential in decreasing the frequency of paracentesis. In a double-blind randomized trial in 55 patients with EOC, Gotlieb et al reported that although aflibercept (4 mg/kg iv every 2 weeks) significantly extended time to ascitic drainage compared with placebo (55.1 versus 23.3 days, respectively; $P=0.0019$), there was no effect on OS.31 Furthermore, it was associated with more grade 3/4 toxicities, including fatal GI adverse effects.31 The current Australia and New Zealand Gynaecological Oncology Group (ANZGOG) REZOLVE II study aims to address whether the intraperitoneal administration of aflibercept could result in OS advantages not witnessed in the Gotlieb trial.

Nintedanib

Nintedanib (BIBF 1120) was the first triple angiokinase inhibitor developed with the principle of impeding tumor angiogenesis at multiple levels through targeting VEGF, fibroblast growth factor (FGF), and platelet-derived growth factor (PDGF). The first placebo-controlled Phase II study investigating nintedanib (250 mg twice daily) in 83 patients with recurrent EOC revealed some PFS advantages that were offset by significantly more GI toxicities.32 A subsequent double-blind Phase III study in the first-line setting comparing nintedanib combined with either carboplatin/paclitaxel or placebo confirmed significantly prolonged PFS with the
nintedanib/chemotherapy group (18.3 versus 16.6 months; HR, 0.84; 95% CI, 0.72–0.98; P=0.0239).13

Trebananib (AMG 386)
The interaction between angiopoietin (Ang) 1 and Ang-2 ligands and their respective Tie-2 receptors within the angiopoietin signaling axis plays an integral role in the stabilization of tumor vascular integrity.34 Trebananib (AMG 386), a neutralizing peptide developed to block Ang-1/Ang-2 and Tie-2 binding, has garnered some interesting results in a series of consecutive TRINOVA Phase III studies for patients with primary or relapsed EOC. The first of these trials (TRINOVA-1; n=919) focused on the combination of paclitaxel with either trebananib or placebo with the trebananib-containing group associated with significant extension in PFS (7.2 versus 5.4 months; HR, 0.66; 95% CI, 0.57–0.77; P<0.001).35 The subsequent TRINOVA-2 (n=223; pegylated liposomal doxorubicin with trebananib or placebo in recurrent EOC; Clinicaltrials.gov identifier NCT01281254) and TRINOVA-3 (n=2,000; EOC first-line therapy with carboplatin/paclitaxel with trebananib or placebo; NCT01493505) interim analyses are awaited.

Pazopanib
Pazopanib is a multifunctional tyrosine kinase inhibitor that principally targets VEGFR (VEGFR-1, VEGFR-2, VEGFR-3), platelet derived growth factor receptor (PDGFR) (PDGFRα and PDGFRβ), fibroblast growth factor receptor (FGFR), and c-kit. Additional targets include colony-stimulating factor 1, lymphocyte-specific tyrosine kinase, and interleukin (IL)-2-inducible T-cell kinase.36 Its broad spectrum of antiangiogenic activity has forged some success in treating renal clear cell carcinoma and soft tissue sarcoma. However, after a small selection of Phase II and III studies, pazopanib is now emerging as an effective novel therapeutic agent in EOC. Friedlander et al published one of the first reports of its efficacy in a Phase II open-label study conducted in 36 patients with recurrent disease taking 800 mg pazopanib daily.37 Eleven patients (31%) obtained CA-125 response (95% CI, 16%–48%). Furthermore, the median response duration was 113 days, with 18% ORR in patients with measurable disease.33 Numerous additional Phase I/II studies are currently investigating the use of pazopanib in combination with various cytotoxic agents as a salvage regimen in the platinum-resistant setting.36 One such study is the Phase I/II Study of Pazopanib (GW786034) and Cyclophosphamide in Patients With Platinum-resistant Recurrent, Pre-treated Ovarian Cancer (PACOVAR), which aims to investigate the feasibility and efficacy of pazopanib in combination with metronomic cyclophosphamide. Conceptually, this is particularly intriguing in view of the potential additive antiangiogenic effects that could be realized with this strategy. Although a plethora of studies are ongoing for recurrent/resistant EOC, there has been some recent excitement generated from a Phase III study investigating pazopanib as a maintenance therapy in the first-line setting.38 Du Bois et al studied 940 patients with historically proven EOC, primary peritoneal (PPC), or fallopian tube cancer (stage II–IV) and no evidence of progressive disease after primary platinum-paclitaxel-based chemotherapy. Subsequently, evaluable subjects were randomized to receive either 800 mg pazopanib daily or placebo for up to 2 years. Interestingly, maintenance pazopanib significantly prolonged median PFS compared with placebo by 5.6 months (17.9 versus 12.3 months, respectively; HR, 0.77; 95% CI, 0.64–0.91; P=0.0021).38 Inevitably, this was slightly offset by grade 3/4 toxicities, with hypertension (30.8%), neutropenia (9.9%), hepatotoxicity (9.4%), and diarrhea (8.2%) being the most frequently encountered.38 Although OS advantages have yet to be seen, the authors speculate that this may eventuate with future subgroup analyses.38

Sunitinib and sorafenib
Sunitinib also displays potent antiangiogenic properties through inhibition of multiple kinases, including VEGF, PDGF, c-Kit, and FMS-like tyrosine kinase-3 (Flt-3).39 To date, data confirming the potential efficacy of this agent emanate from three monotherapeutic Phase II studies in patients with recurrent EOC. Initial reports suggested that sunitinib (50 mg/day orally 4 of 6 weeks) yielded only modest benefits. In 30 evaluable patients with recurrent EOC/PPC, Biagi et al noted only a 3.3% PR rate and 10% CA-125 response, which was only evident in platinum-sensitive disease.40 A subsequent larger study (n=73) randomized patients with recurrent platinum-resistant ovarian cancer to either intermittent (50 mg/day, 4 of 6 weeks) or continuous (37.5 mg/day) dosing of sunitinib.41 The authors reported an ORR of 16.7% versus 5.4% (median PFS, 4.8 versus 2.9 months; median OS, 13.6 versus 13.7 months for the intermittent and continuous groups, respectively).41 The most recent trial in this same setting by Campos et al similarly showed a poor ORR of 8.3% and median PFS of 9.9 weeks.42 Of note, in all aforementioned trials, common adverse effects included hypertension, GI toxicity, hand–foot syndrome, and fatigue.

Sorafenib represents another multi-tyrosine kinase inhibitor (targeting VEGFR, PDGFR, and c-Kit kinases), which exhibits a modicum of activity in EOC. A Phase II
study by Matei et al (n=71) observed the effects of sorafenib monotherapy (400 mg orally twice daily) in recurrent ovarian cancer and revealed a 3.4% PR rate alongside a significant incidence of grade 3/4 toxicities mainly involving skin rash and GI and metabolic effects.\textsuperscript{43} In view of this, later studies have focused on combinatorial trials with chemotherapy or as maintenance therapy in the first-line setting, but they have equally shown poor tolerability and no PFS or OS advantage over chemotherapy alone.\textsuperscript{44,45}

Cediranib
In parallel with the aforementioned multiangiogenic targeted therapies, cediranib (oral anti-VEGFR-1, VEGFR-2, VEGFR-3, and c-kit) also serves as an effective therapeutic strategy with some favorable results generated from both Phase II and III studies. Matulonis et al treated 46 patients with recurrent EOC, PPC, or fallopian tube cancer with oral cediranib originally dosed at 45 mg daily.\textsuperscript{46} This was eventually reduced to 30 mg because of significant toxicities in the initial stages of the study. Encouragingly, 17% of the patients achieved PR, and 13% SD, resulting in a 30% clinical benefit rate. Median PFS was 5.4 months, and the OS has not been reached to date. Grade 3 toxicities were evident in more than 20% of cases, and most included hypertension, diarrhea, and fatigue.\textsuperscript{46} This trial laid the foundations for the two-stage three-arm Phase III ICON6 trial, which observed the effects of cediranib (20 mg daily) in patients with recurrent platinum-sensitive disease (ie, platinum-free interval >12 months).\textsuperscript{47} Patients were equally randomized to standard chemotherapy (ie, platinum doublet), concurrent chemotherapy and cediranib, or concurrent therapy followed by maintenance cediranib. With restricted mean survival times the concurrent maintenance group conferred significant superiority over standard treatment in terms of both PFS (12.6 versus 9.4 months; HR 0.68; 95% CI, 0.54–0.87; log rank test \(P=0.0022\)) and OS (20.3 versus 17.6 months; HR, 0.70; 95% CI, 0.51–0.99; \(P=0.0419\)).\textsuperscript{47}

Targeting type I ovarian cancer
In contrast to high-grade serous ovarian cancer (HGSC), type I ovarian cancers behave as biologically distinct entities and are commonly resistant to chemotherapy. Therefore, the advent of targeted therapies is particularly promising for the management of this challenging patient cohort. In contrast to type II ovarian tumors, which have a high frequency of p53 mutations and genetic instability, type I tumors (which include low-grade serous, endometrioid, mucinous, and clear cell carcinomas) more often have mutations in genes encoding protein kinases and other signaling molecules, including Kras, BRAF, PI3KCA and Erb2, CTNNB1, and PTEN.\textsuperscript{48} As a consequence, this provides a range of novel therapeutic targets (Table 2).

Low-grade serous ovarian carcinoma
Low-grade serous carcinoma (LGSC) of the ovary, although generally having a more indolent course, has notably extremely poor response rates to chemotherapy.\textsuperscript{49,50} LGSC is purported to develop in a stepwise process of tumorigenesis, progressing from serous cystadenomas to serous borderline tumors and, eventually, to invasive LGSC. This is notably distinct from the pathway of development of HGSC, where p53 is commonly mutated.\textsuperscript{51,52} Furthermore, the LGSC group is frequently characterized by driver mutations in the MAPK pathway, which has created a surge of interest in small molecules targeting this pathway.\textsuperscript{51}

### Table 2: Targeted therapeutics in type I epithelial ovarian cancer

<table>
<thead>
<tr>
<th>Histology</th>
<th>Genetic mutation</th>
<th>Targeted therapy</th>
<th>Size</th>
<th>Phase</th>
<th>Treatment arms</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low grade serous papillary</td>
<td>MAPK</td>
<td>Selumetinib (MEK1/2 inhibitor)\textsuperscript{53}</td>
<td>52</td>
<td>II</td>
<td>Selumetinib</td>
<td>15% response rate. Complete response 1/52 patients</td>
</tr>
<tr>
<td>Low grade endometrioid</td>
<td>CTNNB1</td>
<td>No specific trials done in patients with endometrioid histology mTOR trials may have clinical utility</td>
<td>na</td>
<td>na</td>
<td>na</td>
<td>na</td>
</tr>
<tr>
<td></td>
<td>PIK3CA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>PTEN</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>KRAS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>BRAF</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mucinous carcinoma</td>
<td>HER2 (20%)\textsuperscript{52}</td>
<td>Case reports of response to Trastuzumab\textsuperscript{55}</td>
<td>na</td>
<td>na</td>
<td>na</td>
<td>3 patients with mucinous histology demonstrated response to trastuzumab</td>
</tr>
<tr>
<td>Clear cell carcinoma</td>
<td>ARID1A</td>
<td>Sunitinib\textsuperscript{19}</td>
<td>2</td>
<td>na</td>
<td>Sunitinib</td>
<td>2 patients with clear cell histology demonstrated response to sunitinib</td>
</tr>
<tr>
<td></td>
<td>PIK3CA</td>
<td></td>
<td></td>
<td></td>
<td>only arm</td>
<td></td>
</tr>
<tr>
<td></td>
<td>IL-6 overexpression</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Abbreviation:** na, not applicable.
The MEK inhibitors have been trialed in this population with some success. The GOG Phase II trial of selumetinib (a MEK 1/2 inhibitor) in 52 patients with recurrent LGSC reported a response rate of 15% and 65% of patients with stable disease. One patient had a complete response, two (6%) patients had BRAF mutations, and 14 (41%) had KRAS mutations, but there was no significant correlation between mutational status and response to treatment. Another MEK inhibitor trial, MILO (MEK inhibitor in Low-Grade Serous Ovarian Cancer), a Phase III trial of MEK162 versus physician’s choice of chemotherapy in patients with recurrent or persistent low-grade serous carcinomas of ovary, fallopian tube, or PPC, is currently open and aiming to recruit 300 patients internationally, including assessments of their mutational status (NCT01849874). An international randomized Phase II/III study of another MEK inhibitor, trametinib, compared with standard therapy is also under development for women with recurrent LGSC, again with a more extensive plan to characterize mutational status and correlate it to treatment response (NCT02010788). In view of potential resistance to MEK being mediated via the PI3K/AKT pathway, preclinical studies suggest that dual blockade of these pathways may result in greater efficacy, and a trial is currently being developed to investigate this further.

Another potential treatment avenue is using the wild-type p53 gene in patients with LGSC. Nutlin-2 is an inhibitor of p53 breakdown, which binds to the pocket of murine double minute, where it binds TP53 and mediates rapid degradation of TP53 through the ubiquitin-proteasome pathway. Inhibiting this pathway can increase expression of wild-type TP53 and induce apoptosis and has been proposed as a possible therapeutic target not yet addressed by any investigational agent.

Ovarian clear cell carcinoma

Ovarian clear cell cancer (OCCC) patients also experience disappointing responses to chemotherapy, whether it is standard carboplatin/paclitaxel or alternative regimens such as irinotecan/cisplatin. From a genomic perspective, up to 50% of OCCEs are characterized by somatic inactivating mutations in AT-rich interactive domain-containing protein 1A (ARID1A), and more than 30% of cases consist of activating mutations in the p110α catalytic subunit of PI3K (PIK3CA). Although a small Phase II study is currently investigating the addition of temsirolimus (mTOR inhibitor) to standard first-line chemotherapy (NCT01196429), to date, there are a paucity of trials confirming the efficacy of targeting the PI3K signaling pathway in OCCC. Another omnipresent feature in this subtype is the overexpression of the proinflammatory cytokine IL-6, which could also represent a potential therapeutic target. Furthermore, emerging in vivo and clinical evidence suggests that sunitinib may be an effective therapy for OCCC. Sunitinib has been reported to have some clinical efficacy in the setting of platinum-resistant clear cell ovarian cancer. Moreover, Anglesio et al highlighted two cases of patients with OCCC that had progressed on platinum chemotherapy who had a response to sunitinib. Clearly, more extensive clinical investigation is warranted for these approaches before they are incorporated into standard therapeutic management.

Mucinous ovarian carcinoma

In parallel with LGSC and clear cell subtypes, mucinous ovarian carcinomas are also more resistant to carboplatin/paclitaxel than HGSC. As these tumors have more biological similarities to colorectal tumors, the GOG0241 study was conceived to assess the appropriateness of applying standard regimens in this disease to mucinous ovarian carcinosas. This Phase III study recruited patients in the United States and the United Kingdom and compared carboplatin and paclitaxel +/- bevacizumab versus oxaliplatin and capecitabine +/- bevacizumab as first-line therapy in newly diagnosed or recurrent mucinous ovarian carcinomas (NCT01081262). Unfortunately, this study has recently been suspended because of poor patient accrual.

Mucinous carcinomas have also been found to overexpress human epidermal growth factor receptor 2 (HER2) at a rate of about 20%. Trastuzumab has only been investigated in a single Phase II trial of unselected ovarian cancer patients, but further trials in the HER2 overexpressing subpopulation

Table 3 PARP inhibitors in clinical development

<table>
<thead>
<tr>
<th>PARP inhibitor</th>
<th>Delivery</th>
<th>Development phase</th>
<th>Company</th>
</tr>
</thead>
<tbody>
<tr>
<td>Olaparib (AZD2281, KU-0059436)</td>
<td>Oral</td>
<td>I, II, III</td>
<td>AstraZeneca</td>
</tr>
<tr>
<td>Veliparib (ABT888)</td>
<td>Oral</td>
<td>I, II, III</td>
<td>Abbott</td>
</tr>
<tr>
<td>Rucaparib (AGO14699, AG14447, PF-0136738)</td>
<td>Intravenous/oral</td>
<td>I, II, III</td>
<td>Clovis Oncology, Pfizer</td>
</tr>
<tr>
<td>Niraparib (MK4827)</td>
<td>Oral</td>
<td>I, II, III</td>
<td>Tesaro/Merck</td>
</tr>
<tr>
<td>BMN673</td>
<td>Oral</td>
<td>I, II</td>
<td>Biomarin</td>
</tr>
</tbody>
</table>

Abbreviation: PARP, Poly(adenosine diphosphate [ADP]-ribose) polymerase.
would be of interest. In this Phase II trial of trastuzumab in patients with all types of advanced ovarian cancer and HER2 over-expression exhibited an ORR of 7.3% (of 45 patients), with one CR and two PRs. There are isolated reports in the literature of patients with HER2 amplified mucinous ovarian cancers responding to trastuzumab therapy. McAlpine et al reported a series of three patients with mucinous ovarian cancers who received trastuzumab with chemotherapy with some apparent clinical utility.

**Endometrioid ovarian carcinoma**

Endometriosis is associated with endometrioid ovarian carcinomas, which also exhibit distinct pathways of tumorigenesis. Endometrioid ovarian carcinomas have been found to harbor a range of mutations in cell signaling pathways, including activating mutations in CTNNB1, which encodes β-catenin, and PIK3CA (approximately 20% mutation rate), in addition to PTEN (~20%) and less commonly, in KRAS and BRAF. Given this, it is possible that the mTOR inhibitors may have efficacy in this population. mTOR inhibitors have been used in a number of Phase I and Phase II trials in the treatment of EOC patients. Temsirolimus was studied as a single agent in an unselected population of patients with recurrent EOC and was found to have ORR of 9.3%. In the unselected population, as a single agent, in combination with chemotherapy, or in combination with bevacizumab, early results have been fairly disappointing. However, in a more select population, possibly with endometrioid histology, a higher level of efficacy may be seen.

**Poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitors**

Nearly a decade ago, preclinical data emerged suggesting a role for inhibitors of the poly(adenosine diphosphate [ADP]-ribose) polymerases (PARPs) in treating tumors with deficient DNA repair by homologous recombination (Table 3). The PARP enzymes play a vital role in cellular DNA repair, coordinating base-excision repair pathways. Inhibition of PARP results in an excess of single-strand breaks, which causes double-strand breaks during replication. Such defects are usually repaired by homologous recombination, a highly efficient process requiring intact BRCA proteins. Tumors with defective homologous recombination, including BRCA1/2 mutation-associated cancers, display particular sensitivity to PARP inhibition. In this situation, double-stranded DNA breaks are repaired by homologous end joining, which is error prone and causes genomic instability and cell death. This approach exploits the concept of synthetic lethality, in which significant lethal synergy occurs between two otherwise nonlethal events or, in this scenario, where PARP inhibition in the setting of defective BRCA protein leads to tumor cell death.

Female carriers of germline mutations in *BRCA1* and *BRCA2* are at high risk of developing ovarian cancer, with lifetime risks of nearly 40% and 11%, respectively. Mutation in *BRCA1* or *BRCA2* is seen in 10%–20% of ovarian cancers, and defects in other homologous recombination pathway genes in a further 6%. However, in the most common form of malignant epithelial ovarian cancer, HGSC, defects in homologous recombination occur in up to 50% of cases, including germline or somatic loss-of-function mutations of *BRCA1* or *BRCA2*, epigenetic silencing of *BRCA1*, and defects in other genes in this class including *RAD51D, ATM, PALB2, RAD51C*, and *BRIP1*. Patients with homologous recombination-deficient ovarian cancer typically demonstrate a “BRCAness” phenotype that is similar to that of patients with BRCA-mutated tumors, who generally exhibit better outcomes compared with patients with sporadic ovarian cancer, including improved platinum sensitivity and overall survival.

The mechanism of action of small molecule inhibitors of PARP are, first, catalytic inhibition of repair of single-strand breaks and second, trapping of PARP on DNA forming cytotoxic PARP-DNA complexes. The first in-human trial of an oral PARP inhibitor, olaparib, was undertaken in patients with refractory solid tumors and was noteworthy for evidence of antitumor response in the subset of patients with known BRCA mutations and the absence of significant toxicity. The maximum tolerated dose was 400 mg twice daily, and the most common toxicities were mild fatigue, nausea, and vomiting. In an expansion cohort of this study in BRCA carriers with ovarian cancer, durable responses were seen correlating with platinum sensitivity. The response rate in platinum-sensitive patients was 69% compared with 45% in platinum-resistant patients and 23% in those with platinum refractory disease.

In a Phase II trial of olaparib in patients with *BRCA*-mutated recurrent ovarian cancer, there was evidence of a dose-response relationship, with a response rate of 13% at 100 mg twice daily compared with 33% at 400 mg twice daily. Common adverse events included mild to moderate fatigue, nausea, diarrhea, and anemia. In a second Phase II study of olaparib in patients with recurrent high-grade serous or undifferentiated ovarian cancer with or without *BRCA1/2* mutation, there was objective response in 41% of mutation-positive patients compared with 24% patients...
with sporadic disease. In both groups of patients, response rates were higher in those with platinum sensitivity, as seen previously.

This was followed by a randomized open-label Phase II trial of olaparib compared with standard therapy with pegylated liposomal doxorubicin (PLD) in patients with germline *BRCA* mutations and recurrent ovarian cancer after platinum failure. Olaparib 200 mg and 400 mg twice daily demonstrated response rates of 25% and 31%, respectively, compared with 18% with PLD, but there was no significant difference in PFS. There was improved tolerability of olaparib compared with PLD, suggesting PARP inhibition would be a reasonable option for this patient group.

Olaparib has also been investigated as maintenance monotherapy for platinum-sensitive relapsed HGSC. In a randomized placebo-controlled Phase II trial, olaparib demonstrated a PFS of 8.4 months compared with 4.8 months with placebo (HR for progression or death, 0.35; 95% CI, 0.25–0.49; *P*<0.001). A preplanned subgroup analysis after retrospective determination of *BRCA* status highlighted significant prolongation of PFS in *BRCA*-mutated patients with olaparib (11.2 months, versus 4.3 months with placebo). In patients without *BRCA* mutation, there was a less pronounced increase in PFS with olaparib (7.4 months compared with 5.5 months with placebo). There was no benefit in terms of OS in an interim analysis; however, 23% of *BRCA*-mutated patients who received placebo were eligible for PARP inhibitor therapy at progression. In view of this, as of June 2014, the US Food and Drug Administration’s Oncological Drugs Advisory Committee has voted against the accelerated use of olaparib in this setting. However, Phase III trials are under way to further evaluate the role of olaparib in patients with *BRCA*-mutated ovarian cancer after first-line platinum-based chemotherapy (Olaparib Monotherapy in Patients With *BRCA* Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy [NCT01844986]) and in *BRCA*-mutated patients with recurrent platinum-sensitive, high-grade serous cancer (Olaparib Treatment in *BRCA* Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy [NCT01874353]). Hence, it appears that future Oncological Drugs Advisory Committee approval for olaparib is needed to further investigate the role of olaparib in ovarian cancer.

PARP inhibitors have also been investigated in combination with chemotherapy as a result of potential synergy with platinum agents suggested in preclinical models. Initial Phase I studies of cytotoxics and olaparib have demonstrated dose-limiting myelosuppression requiring intermittent dosing of olaparib. However, promising antitumor activity was demonstrated in a Phase I trial of olaparib (50 mg twice a day, days 1–5) and cisplatin (60 mg/m²), with an ORR of 43% in patients with relapsed *BRCA1/2* mutated ovarian cancer. Carboplatin (AUC 5) has also been assessed in combination with olaparib (400 mg twice a day, days 1–7), with a response rate of 44% in patients with recurrent ovarian cancer. In both of these studies, nearly half of the patients required growth factor support, and it is likely that hematologic toxicity will impose challenges in the further investigation of these combinations. Olaparib has also been investigated in combination with the antiangiogenic agent cediranib, with promising results presented at ASCO 2014. In a randomized Phase II trial in patients with recurrent platinum-sensitive high-grade serous or *BRCA*-mutated ovarian cancer, interim analysis revealed a response rate of 84% in patients receiving cediranib plus olaparib. The median PFS was 17.7 months in patients receiving both agents compared with 9.0 months in patients receiving olaparib monotherapy. However, the interim analysis also noted an unexpected PFS advantage with the combination group for *BRCA* wild-type/unknown (16.5 months in the combination group versus 5.7 months for olaparib; *P*=0.008) compared with *BRCA*-mutated patients (PFS of 19.4 months in the combination group versus 16.5 months with olaparib; *P*=0.16). It has to be noted that stratification of *BRCA* status for PFS was not a prespecified study endpoint. In addition, this study did not contain a comparative cediranib monotherapy group. Nevertheless, this interesting finding clearly requires further investigation.

There are a number of other PARP inhibitors in early clinical development. Niraparib, a novel inhibitor of PARP1 and PARP2, demonstrated a 40% response rate in *BRCA*-mutated ovarian cancer in a Phase I trial, including a median duration of response of 431 days. Niraparib is being further explored in a randomized placebo-controlled Phase III trial as maintenance therapy in patients with platinum-sensitive *BRCA*-mutated ovarian cancer or HGSC (Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer [NCT01847274]).

As PARP inhibitors are still relatively new agents in the clinical arena, mechanisms of therapeutic resistance are largely based on preclinical models. To date, mechanisms of resistance include secondary mutations that restore functional *BRCA1* or *BRCA2* genes, reduced expression of nonhomologous end-joining factor 53BP1, and increased cellular drug efflux via increased expression of the P-glycoprotein pump. Elucidating the clinical effect of these putative resistance pathways requires clinical trial designs that...
incorporate repeat blood and tumor sampling at progression to allow comprehensive biomarker and genomic analyses.

**The HER family**

The ERBB/HER family of receptor tyrosine kinases plays a key role in cell growth and survival, and dysregulation is implicated in the pathogenesis of numerous malignancies. The epidermal growth factor receptor (EGFR or ERBB1) is expressed in 25%–50% of ovarian cancers, with conflicting data in terms of the prognostic implications. Clinical trials of EGFR inhibition in ovarian cancer have been disappointing to date. Phase II trials with cetuximab (EGFR chimeric monoclonal antibody) and gefitinib (EGFR tyrosine kinase inhibitor) both demonstrated limited activity in unselected patients with recurrent ovarian cancer. EGFR-activating mutations were present in 3.5% of tumors analyzed, including the only patient on study with an objective response. Similarly, erlotinib showed no benefit compared with observation alone in a randomized Phase III trial of patients with high-risk ovarian cancer after first-line chemotherapy.

With respect to HER2 blockade, Bookman et al conducted a Phase II study using trastuzumab in 837 patients with recurrent or persistent EOC. The authors also reported a low frequency of mandated HER2 overexpression (ie, 2+ or 3+) amounting to 11.4% and found no relationship between HER2 expression and either survival or response to trastuzumab. Furthermore, the 7.3% ORR and 2.0 month PFS seen in this study was far inferior to analogous studies with single agent trastuzumab in breast cancer. In a subsequent GOG study, the rate of HER2 gene amplification by fluorescence in situ hybridization was only 7% and yielded no predictive or prognostic value. Pertuzumab, a recombinant humanized monoclonal antibody and HER dimerization inhibitor, has also demonstrated limited benefit in ovarian cancer, both as a single agent and in combination with platinum chemotherapy.

A more recent report analyzing tissue arrays from 202 ovarian carcinoma patient samples demonstrated high levels of expression of HER3, HER4, and the hepatocyte growth factor, MET. HER3 activation and MET activation were present in 79% and 56% of cases, respectively. HER3 is thought to activate PI3K signaling in EGFR, HER2, and MET oncogene-addicted cancers; it has been associated with a poorer median survival in ovarian cancer. Preclinical work on MM-121, a HER3 monoclonal antibody, demonstrated significant inhibition of tumor growth in ovarian cancer cell lines and in xenograft models. A randomized Phase II trial of MM-121 with paclitaxel in platinum-resistant/refractory advanced ovarian cancer is ongoing (NCT01447706).

**Targeting cancer-related inflammation**

The intricate links between chronic inflammation and tumorigenesis postulated by Virchow in the 19th century have since been established in a host of malignancies. This particular paradigm is lucidly exemplified in EOC, with numerous cytokines and inflammatory cells playing key roles in processes such as tumor cell proliferation, migration, apoptotic evasion, and angiogenesis, which together promote a fertile microenvironment facilitating tumorigenesis. Recent translational studies have witnessed a modicum of success in targeting proinflammatory cytokines such as tumor necrosis factor α (TNF-α) and IL-6 (itself induced by TNF-α), which both act as principal orchestrators for these aforementioned tumorigenic processes. Madhusudan et al conducted a Phase II study with the TNF-α antagonist etanercept. In this trial, six of 30 patients with advanced ovarian cancer showed prolonged disease stabilization, and whole-blood cytokine assay showed a significant decrease in IL-6 levels (11 of 17 patients). In a subsequent Phase I clinical trial in patients with advanced cancer, Brown et al investigated the clinical efficacy and biological activity of infliximab (anti-TNF antibody). In this study, 41 patients with advanced cancer (eight of whom had EOC) received infliximab at 5 mg/kg (n=21) or 10 mg/kg (n=20) iv at 0 and 2 weeks and then every 4 weeks. Before iv infusion of 5 or 10 mg/kg infliximab, IL-6 levels were measured in plasma with levels ranging from undetectable to 35 pg/mL (median, 20 pg/mL). During the antibody infusion, serial samples of plasma were obtained over a 24–96 hour period. Plasma IL-6 levels decreased significantly in all patients at 24 and 48 hours after the first treatment with both doses. However, at the end of the study, IL-6 levels had started to rise, although not significantly. Furthermore, one of the eight patients with EOC attained stable disease. These observations influenced a subsequent Phase II study reported by Coward et al which investigated the efficacy of anti-IL-6 therapy with siltuksam in 18 patients with platinum-resistant EOC. The primary endpoint was response rate as assessed by combined Response Evaluation Criteria in Solid Tumors and CA125 criteria. One patient of 18 who were evaluable had a partial response, and seven others had periods of disease stabilization, four of which were treated for 6 months. None of the serious adverse events reported in the study were attributable to siltuximab, and it was generally well tolerated.

In light of the resounding success of immunotherapy within malignant melanoma and non-small-cell lung cancer, there have been attempts to recapitulate these findings in
EOC. Programmed death 1 (PD-1) is a co-inhibitory receptor expressed on activated T cells, and ligand binding (PD-L1 and PD-L2) acts to regulate antitumor immunity. Nivolumab is a humanized monoclonal antibody that blocks this interaction and has recently been shown to confer some efficacy in a Phase I study in 15 patients (1 mg/kg, n=10; 3 mg/kg, n=5) with platinum-resistant EOC. In 13 evaluable patients, the interim analysis reported three PRs with a duration of response at 4, 5, and 10 months; the low-dose cohort was not associated with any significant adverse effects. With respect to PDL-1 inhibition, Brahmer et al conducted a multicenter Phase I study treating in 207 patients, including 17 with ovarian cancer. Of these, only one obtained an objective response. Although there is a current Phase II study with ipilimumab (anti-CTLA-4 monoclonal antibody), in patients with platinum-sensitive EOC, recruitment has been halted (NCT01611558).

**Folate antagonists**

Folate receptors (FRs), specifically FR-α, are highly expressed in up to 80% of nonmucinous ovarian cancer. FR-α is integral to tumor folate transport and also facilitates chemoresistance and poor survival outcomes. Hence, it intuitively appears to represent a suitable therapeutic target. An initial study with the FR-α monoclonal antibody, farletuzumab, investigated its efficacy given alone and then subsequently in combination with carboplatin/paclitaxel at time of progression in patients with platinum-sensitive recurrence. Objective response was seen in 75% and CA125 declined in 80% of participants. Unfortunately, a follow-up study with farletuzumab in combination with weekly paclitaxel in platinum-resistant/refractory patients failed to reach its end point. However, a current Phase III study is investigating this agent in combination with carboplatin/paclitaxel in the first-line setting. In addition, intriguing results have been reported using an FR antibody conjugate of folic acid and desacetylvinblastine (EC145). In the Phase II PRECEDENT (Platinum Resistant Ovarian Cancer Evaluation of Doxil and Vintafolide [MK-8109, EC145] Combination Therapy [8109-009, EC-FV-04]) study, patients with recurrent platinum-resistant EOC were randomized to either PLD or PLD and EC145, with superior PFS seen in the combination group (24.0 versus 11.7 weeks; P=0.014). Interestingly, using whole-body single-photon emission computerized tomography scanning with Tc-labeled folate, increased response was evident in patients with higher folate receptor expression.

**Insulin signaling inhibition**

The insulin-like growth factor (IGF) system has integral roles in numerous physiologic and pathologic processes. It consists of three ligands (IGF-1, IGF-2, and insulin) and their respective cell surface receptors (IGF-1R, IGF-2R, IR), all of which share a structural and functional homology. Their interaction initiates a surge of downstream signaling events predominantly via Ras-Raf-MAPK and PI3K-Akt transduction pathways, which facilitate tumorogenesis by promoting cellular proliferation, angiogenesis, invasion, and metastatic potential and inhibiting apoptosis. Manipulation of this pathway is currently being explored in various EOC settings. The dual IR/IGFR inhibitor, OSI906, has been investigated as part of a three-armed study in patients with platinum-resistant/refractory disease. The trial has randomized 199 patients to receive weekly paclitaxel either alone or in combination with OSI906, dosed either continuously or intermittently (NCT00889382). The interim analysis is pending. A single-agent IGF monoclonal antibody study in platinum-sensitive disease is currently active (NCT00719212), but from a biologic perspective, the lack of dual IR blockade is likely to potentiate resistance to IGF inhibition. Combinatorial studies with anti-IGFR/PI3K/mTOR inhibitors are also currently under way (NCT01243762).

**Conclusion**

In comparison to the significant advances in survival witnessed in other malignancies, undoubtedly, progress in this respect with EOC has been relatively sluggish. Taking into consideration the recent progress in our understanding of the biology of this disease, particularly with the type I and II dichotomy, it is appears counterintuitive to treat such a disparate collection of subtypes identically. Although the gold standard of the carboplatin and paclitaxel doublet regimen has remained the “soup de jour” for more than a decade, small increments in extending OS have only been realized with the addition of targeted therapies described in this review within the last few years. However, despite some encouraging results, such novel regimens have yet to become established treatments approved by the US Food and Drug Administration in EOC. Again, this highlights a significant gulf in the evolution of targeted agents that have now become embedded as standard of care in tumor types including breast, colorectal, and lung cancers. Specifically, the success witnessed in these tumor types was ultimately born from appropriate patient stratification. Unquestionably, the effect of trastuzumab, cetuximab, and erlotinib for these respective diseases would not have emerged without this stratification.

There is certainly evolving evidence of this practice bearing fruit in EOC. This has clearly been exemplified by the ICON7 subgroup analysis confirming that the OS advantage for first-line bevacizumab is restricted to patients...
with suboptimally debulked disease. It appears that such stratification could be enriched even further by the data presented by Gourley et al at ASCO 2014, whereby patients with a proangiogenic gene signature had significantly improved PFS when treated with carboplatin/paclitaxel and bevacizumab compared with chemotherapy alone. However, it appears that the addition of bevacizumab was detrimental to PFS in the immunogenic subgroup.

With respect to PARP inhibition with olaparib in maintenance treatment for recurrent platinum-sensitive HGSC, PFS advantages appear to be enhanced in BRCA-mutated patients compared with BRCA wild-type. However, intriguing observations have been noted with combinations of olaparib and cediranib, in which PFS was significantly extended with this doublet over olaparib alone for BRCA wild-type/unknown status but not for BRCA-mutated patients. Hence this adds a new level of complexity to the stratification of patients for PARP inhibition when combined with other agents.

Another area of burgeoning excitement surrounds targeted therapy for type I EOC. By definition, low-grade tumors are inherently chemoresistant, yet chemotherapy still represents the standard of care for these diseases, which generally exhibit 4% ORR with this approach. For this reason alone, there is a desperate urge to change this outmoded paradigm. Moreover, these subtypes are signified by particular aberrant signaling pathways, which can be targeted by novel small molecule inhibitors. Indeed, this has resulted in numerous studies investigating the efficacy of MEK blockade in LGSC.

Furthermore, there is evidence confirming that lessons are being learned with the use of agents established in non-ovarian malignancies for EOC subtypes that share biological similarities to these diseases. For example, sunitinib, which is standard first-line therapy for metastatic renal clear cell carcinoma, has shown efficacy in OCCE and is now being further investigated in Phase II studies (NCT01824615 and NCT00979992). Similarly, the benefits of PI3K/mTOR inhibitors with endometrioid endometrial cancer certainly serve as a platform for developing studies with these drugs in endometrioid EOC.

Undoubtedly, future challenges will revolve around evading resistance to these new therapies, and various combinatorial studies are being designed to address these issues. Nevertheless, by expanding on these aforementioned trials with a deeper appreciation for the heterogeneity of EOC, it is certainly feasible that significant prolongation of survival could be achieved by adopting this philosophy.

Disclosure
The authors report no conflicts of interest in this work.

References
58. Kurman RJ, Shih IeM. Molecular pathogenesis and extravaarian origin of epithelial ovarian cancer – shifting the paradigm. Hum Pathol. 2011;42(7):918–931.


